Takeda announced the availability of Entyvio (vedolizumab) injection for the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn’s disease (CD). The FDA approved Entyvio in May 2014.

Entyvio, an integrin receptor antagonist, is a humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin and blocks the interaction of alpha4beta7 integrin with mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and inhibits the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue. The interaction of the alpha4beta7 integrin with MAdCAM-1 has been implicated as an important contributor to the chronic inflammation that is present in ulcerative colitis and Crohn’s disease.

RELATED: Entyvio Injection Approved for UC, Crohn’s Disease

Entyvio is available in 20mL single-use vials containing 300mg vedolizumab.

For more information call (877) 825-3327 or visit Entyvio.com.